302 related articles for article (PubMed ID: 27147897)
21. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.
Xu D; Allsop SA; Witherspoon SM; Snider JL; Yeh JJ; Fiordalisi JJ; White CD; Williams D; Cox AD; Baines AT
Carcinogenesis; 2011 Apr; 32(4):488-95. PubMed ID: 21262926
[TBL] [Abstract][Full Text] [Related]
22. Critical role of NF-κB in pancreatic cancer.
Prabhu L; Mundade R; Korc M; Loehrer PJ; Lu T
Oncotarget; 2014 Nov; 5(22):10969-75. PubMed ID: 25473891
[TBL] [Abstract][Full Text] [Related]
23. Comparison of tumour and serum specific microRNA changes dissecting their role in pancreatic ductal adenocarcinoma: a meta-analysis.
Chhatriya B; Mukherjee M; Ray S; Sarkar P; Chatterjee S; Nath D; Das K; Goswami S
BMC Cancer; 2019 Dec; 19(1):1175. PubMed ID: 31795960
[TBL] [Abstract][Full Text] [Related]
24. Roles of lncRNAs in pancreatic ductal adenocarcinoma: Diagnosis, treatment, and the development of drug resistance.
Jiang XY; Zhu QC; Zhang XJ; Duan T; Feng J; Sui XB; Sun XN; Mou YP
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):128-139. PubMed ID: 36543619
[TBL] [Abstract][Full Text] [Related]
25. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
[TBL] [Abstract][Full Text] [Related]
26. Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance.
Palamaris K; Felekouras E; Sakellariou S
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771695
[TBL] [Abstract][Full Text] [Related]
27. A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma.
Bradney MJ; Venis SM; Yang Y; Konieczny SF; Han B
Small; 2020 Mar; 16(10):e1905500. PubMed ID: 31997571
[TBL] [Abstract][Full Text] [Related]
28. Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition.
Mizuuchi Y; Aishima S; Ohuchida K; Shindo K; Fujino M; Hattori M; Miyazaki T; Mizumoto K; Tanaka M; Oda Y
Lab Invest; 2015 Feb; 95(2):193-206. PubMed ID: 25418581
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R
Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028
[TBL] [Abstract][Full Text] [Related]
30. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
[TBL] [Abstract][Full Text] [Related]
31. NF-κB and Pancreatic Cancer; Chapter and Verse.
Silke J; O'Reilly LA
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572737
[TBL] [Abstract][Full Text] [Related]
32. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.
Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X
Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088
[TBL] [Abstract][Full Text] [Related]
33. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
34. The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer.
Entrialgo-Cadierno R; Cueto-Ureña C; Welch C; Feliu I; Macaya I; Vera L; Morales X; Michelina SV; Scaparone P; Lopez I; Darbo E; Erice O; Vallejo A; Moreno H; Goñi-Salaverri A; Lara-Astiaso D; Halberg N; Cortes-Dominguez I; Guruceaga E; Ambrogio C; Lecanda F; Vicent S
Mol Cancer; 2023 May; 22(1):86. PubMed ID: 37210549
[TBL] [Abstract][Full Text] [Related]
35. Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer.
Sannino G; Armbruster N; Bodenhöfer M; Haerle U; Behrens D; Buchholz M; Rothbauer U; Sipos B; Schmees C
Oncotarget; 2016 Nov; 7(45):73725-73738. PubMed ID: 27713160
[TBL] [Abstract][Full Text] [Related]
36. Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling.
Kuo SH; Yang SH; Wei MF; Lee HW; Tien YW; Cheng AL; Yeh KH
Cancer Cell Int; 2021 Aug; 21(1):436. PubMed ID: 34412631
[TBL] [Abstract][Full Text] [Related]
37. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
38. Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment.
Bhatia R; Bhyravbhatla N; Kisling A; Li X; Batra SK; Kumar S
Semin Cancer Biol; 2022 Nov; 86(Pt 2):499-510. PubMed ID: 35346801
[TBL] [Abstract][Full Text] [Related]
39. Tumor-neuroglia interaction promotes pancreatic cancer metastasis.
Su D; Guo X; Huang L; Ye H; Li Z; Lin L; Chen R; Zhou Q
Theranostics; 2020; 10(11):5029-5047. PubMed ID: 32308766
[No Abstract] [Full Text] [Related]
40. Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review.
Wang S; Huang S; Sun YL
Biomed Res Int; 2017; 2017():2646148. PubMed ID: 29379795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
